Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s

Contributed by: Business Wire

Logo

Tags

Research

Nursing

Neurology

Clinical Trials

Biotechnology

Managed Care

Health

Pharmaceutical

Science

Results of Phase 2b ACTIVATE study of BIA 28-6156 on Parkinson’s

More Like This

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156

PR Newswire associated0

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Bial Launches Education and Awareness Campaign for World Parkinson’s Day

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease